CD274 and neoplasm: These observations in this advanced, heavily pre-treated patient population warrant further development of domatinostat in combination with anti-PD-(L)1 antibodies to sensitize the tumor, the tumor microenvironment and the patient’s immune response for synergistic anti-tumor activity (Fig. 1).